CRISPR Therapeutics (CRSP) PT Lowered to $150 at JMP Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts CRSP Hot Sheet
Price: $51.42 -5.23%
Rating Summary:
19 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
19 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
JMP Securities analyst Silvan Tuerkcan lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $150.00 (from $155.00) while maintaining a Market Outperform rating.
You May Also Be Interested In
- Evercore ISI Downgrades Reddit (RDDT) to In Line, Removes From Tactical Outperform List
- Norwegian Cruise (NCLH) PT Raised to $22 at Freedom Broker, Upgrades to Buy
- Eli Lilly (LLY) PT Raised to $1,600 at Freedom Broker
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
